Proteomics International has been granted a Canadian patent for its PromarkerEso blood test, a pioneering diagnostic tool for early detection of esophageal adenocarcinoma. This milestone strengthens its global intellectual property portfolio and paves the way for commercial expansion in North America.
- Canadian patent granted for PromarkerEso diagnostic test
- Test detects esophageal adenocarcinoma early via blood biomarkers
- Patent protection now spans Australia, Canada, China, Europe, Hong Kong, and the USA
- Addresses critical unmet need with non-invasive alternative to costly endoscopy
- Potential to improve survival rates and reduce healthcare costs
A Major Step in Cancer Diagnostics
Proteomics International Laboratories Ltd (ASX, PIQ) has secured a significant intellectual property win with the Canadian Patent Office granting a patent for its PromarkerEso blood test. This diagnostic innovation targets esophageal adenocarcinoma (EAC), a form of cancer notorious for late detection and poor survival outcomes. The Canadian patent adds to an expanding portfolio that already covers key markets including Australia, China, Europe, Hong Kong, and the United States.
Addressing a Silent Killer
Esophageal adenocarcinoma ranks among the deadliest cancers globally, with a five-year survival rate below 20% and median survival often less than a year. The disease is frequently linked to chronic acid reflux or gastroesophageal reflux disease (GERD), which affects roughly 20% of the US population. Current screening relies on invasive and expensive endoscopy procedures, which despite their cost and discomfort, fail to detect up to 90% of cases early enough for effective intervention.
Innovation Through Biomarkers
PromarkerEso offers a first-in-class, non-invasive blood test that analyses four key serum glycoproteins combined with patient clinical data such as age, sex, and body mass index. This proprietary algorithm generates a simple 'traffic light' risk score, enabling earlier and more accurate identification of individuals at risk. Early detection could transform patient outcomes and reduce the burden on healthcare systems by avoiding costly procedures and late-stage treatments.
Commercial and Global Health Implications
The Canadian patent, valid until November 2035, secures Proteomics International’s foothold in North America, a critical market for commercialisation, partnerships, and licensing. With rising incidence rates potentially linked to western dietary habits, the demand for efficient and patient-friendly diagnostic tools is urgent. The company’s expanding patent coverage across multiple jurisdictions positions it well to capitalise on this growing need.
Looking Ahead
While the patent grant marks a pivotal milestone, questions remain about the timeline for regulatory approvals, market adoption, and commercial partnerships in North America. Proteomics International’s next moves will be closely watched by investors and healthcare stakeholders eager to see how this innovation translates into real-world impact.
Bottom Line?
With Canadian patent protection secured, Proteomics International is poised to advance PromarkerEso’s global commercial journey, but the path to market adoption remains to be charted.
Questions in the middle?
- When will PromarkerEso receive regulatory approval for clinical use in Canada and the US?
- What commercial partnerships or licensing deals might Proteomics International pursue next?
- How will PromarkerEso compete with existing diagnostic methods and emerging technologies?